Recent Updates
Recently added Catalysts
ALT Positive Sentiment Score: 65/100

Altimmune to Participate in Upcoming Investor Conferences

Tuesday, August 26, 2025 2 min read
Key Takeaway: Altimmune, Inc. has announced its participation in three upcoming investor conferences, including the Wells Fargo Healthcare Conference, the H.C. Wainwright Global Investment Conference, and the Morgan Stanley Global Healthcare Conference. Management will engage in one-on-one meetings and host fireside chats that will be accessible via webcast. The company's focus remains on developing peptide-based therapeutics for liver and cardiometabolic diseases, highlighted by its lead product candidate, pemvidutide.

Market Sentiment Analysis

POSITIVE FACTORS

  • Altimmune is participating in multiple prestigious investor conferences.
  • Management will be available for one-on-one meetings, providing personalized interaction with investors.
  • The company is advancing its late clinical-stage developments in significant therapeutic areas.

Full Press Release Details

GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences:
Wells Fargo Healthcare Conference in Boston, MA
Friday, September 5, 2025
One-on-one meetings only
H.C. Wainwright Global Investment Conference in New York, NY
Tuesday, September 9, 2025
Fireside chat at 8:30 a.m. Eastern Time
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
Morgan Stanley Global Healthcare Conference in New York, NY
Wednesday, September 10, 2025
Fireside chat at 7:45 a.m. Eastern Time
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Chief Financial Officer
jake.robison@inizioevoke.com
This press release was published by a CLEAR® Verified individual.

Frequently Asked Questions

What is the focus of Altimmune, Inc.?

Altimmune, Inc. specializes in peptide-based therapeutics for liver and cardiometabolic diseases.

When is Altimmune participating in the Wells Fargo Conference?

Altimmune will attend the Wells Fargo Conference on September 5, 2025.

Will Altimmune's sessions be available online?

Yes, the sessions will be webcast and accessible on Altimmune's website.

What is Altimmune's lead product candidate?

The lead product candidate is pemvidutide, a dual receptor agonist for various diseases.

How can I contact Altimmune's CFO?

You can contact Altimmune's CFO at jake.robison@inizioevoke.com.

Tags: ALT Viatris Investor Conferences Healthcare Altimmune pemvidutide investor conferences biopharmaceutical MASH
Last updated: Aug 26, 2025